Isaac Barchas Sells 62,291 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 62,291 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $26.23, for a total value of $1,633,892.93. Following the sale, the director directly owned 92,211 shares in the company, valued at $2,418,694.53. This trade represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The shares were sold at an average price of $27.25, for a total transaction of $301,058.00.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The stock was sold at an average price of $26.07, for a total transaction of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Trading Down 5.6%

IMNM opened at $26.42 on Friday. The stock has a 50-day moving average of $22.02 and a 200 day moving average of $22.20. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $28.62. The firm has a market cap of $3.00 billion, a P/E ratio of -10.44 and a beta of 2.08.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, research analysts forecast that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Key Headlines Impacting Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a Buy rating. The new target implies substantial potential upside and helped support investor interest in IMNM, which reached a fresh 52-week high following the upgrade. Truist price target update
• Positive Sentiment: An investment thesis highlighted two potential catalysts: FDA acceptance of varegacestat’s new drug application and a PDUFA decision date in April 2027. Investors are also watching IM-1021, Immunome’s Phase 1 ROR1 antibody-drug conjugate, with initial data expected in 2026. The company believes its proprietary TOP1 inhibitor payload could offer advantages in efficacy, resistance management and bystander effects. Immunome catalysts and pipeline analysis
• Positive Sentiment: Immunome’s second-quarter business update kept attention focused on its antibody-based oncology and infectious-disease pipeline, which remains the primary driver of the company’s valuation and future growth prospects. Immunome second-quarter 2026 results
• Neutral Sentiment: Director Isaac Barchas sold shares in several transactions from August 10 through August 12, including approximately 98,712 shares for about $2.6 million. The sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of current management sentiment, although they may add short-term supply pressure. Immunome director sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the expected loss of $0.51. The earnings miss underscores the company’s ongoing cash-burn and execution risks while its pipeline remains in development.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IMNM. Citigroup restated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Leerink Partners reduced their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Truist Financial increased their target price on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays assumed coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price for the company. Finally, Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.64.

Hedge Funds Weigh In On Immunome

A number of large investors have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new position in Immunome in the 1st quarter worth about $1,507,000. California State Teachers Retirement System grew its stake in Immunome by 66.3% in the first quarter. California State Teachers Retirement System now owns 111,444 shares of the company’s stock worth $2,437,000 after purchasing an additional 44,432 shares in the last quarter. Nan Fung Trinity HK Ltd. increased its holdings in Immunome by 20.7% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock worth $15,349,000 after purchasing an additional 122,450 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after buying an additional 1,144,788 shares during the period. Finally, Edgestream Partners L.P. bought a new position in shares of Immunome during the 1st quarter worth $1,310,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.